Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
[摘要]
[发布日期] [发布机构]
[效力级别] [学科分类] 肿瘤学
[关键词] Recombinant human circularly permuted TRAIL;Phase II trial;Relapsed or refractory multiple myeloma;Efficacy;Safety [时效性]
